Protein structural stabilization

Protein structural stabilization is a therapeutic strategy and physiological process rather than a specific molecular target such as a receptor or enzyme. It refers to the preservation of a protein's functional three-dimensional conformation, which is essential for biological activity and the prevention of proteotoxicity. In many diseases, such as transthyretin amyloidosis or Fabry disease, mutations destabilize specific proteins, leading to their misfolding, degradation, or the formation of toxic aggregates (Source: Nature Reviews Drug Discovery, 2008). Therapeutic intervention via this mechanism involves the use of pharmacological chaperones or kinetic stabilizers. These small molecules bind to the target protein—such as the transthyretin tetramer in the case of Tafamidis—to increase the activation energy required for unfolding, thereby halting disease progression (Source: NEJM, 2018). While highly effective for specific protein-misfolding disorders, this approach is highly target-specific and requires the molecule to stabilize the protein without blocking its essential biological function or interfering with the broader proteostasis network.

Other names

Protein stabilizationConformational stabilizationProteostasis maintenanceKinetic stabilizationPharmacological chaperoning

Binding to the native or near-native state of a protein to decrease the free energy of the folded state, thereby preventing misfolding, aggregation, or premature degradation by cellular quality control systems.